Financhill
Sell
41

GLTO Quote, Financials, Valuation and Earnings

Last price:
$3.03
Seasonality move :
-15.05%
Day range:
$2.86 - $3.10
52-week range:
$2.01 - $16.07
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.32x
Volume:
15.7K
Avg. volume:
69.2K
1-year change:
-80.85%
Market cap:
$4M
Revenue:
--
EPS (TTM):
-$15.54

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
GLTO
Galecto
-- -$2.82 -- -51.46% $8.00
ASND
Ascendis Pharma AS
$107.9M -$1.71 292.42% -21.89% $223.52
EVAX
Evaxion AS
$60K -$0.71 -59.42% -91.42% $13.25
GMAB
Genmab AS
$759.6M $0.23 16.38% 7.82% $29.31
IOBT
IO Biotech
-- -$0.23 -- -3.23% $9.50
NVO
Novo Nordisk AS
$11.9B $0.92 19.3% 36.74% $89.76
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
GLTO
Galecto
$2.99 $8.00 $4M -- $0.00 0% --
ASND
Ascendis Pharma AS
$162.00 $223.52 $9.8B -- $0.00 0% 24.13x
EVAX
Evaxion AS
$1.88 $13.25 $11.9M -- $0.00 0% 0.60x
GMAB
Genmab AS
$20.81 $29.31 $12.8B 12.37x $0.00 0% 4.36x
IOBT
IO Biotech
$1.21 $9.50 $79.7M -- $0.00 0% --
NVO
Novo Nordisk AS
$67.35 $89.76 $299.3B 19.95x $1.10 2.4% 6.89x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
GLTO
Galecto
-- 1.269 -- --
ASND
Ascendis Pharma AS
128.87% 0.179 9.75% 0.67x
EVAX
Evaxion AS
-- -0.376 -- 2.80x
GMAB
Genmab AS
-- 0.045 -- 5.32x
IOBT
IO Biotech
-- -3.128 -- --
NVO
Novo Nordisk AS
46.15% 1.792 5.59% 0.54x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
GLTO
Galecto
-- -$2.6M -- -- -- -$2.4M
ASND
Ascendis Pharma AS
$87.8M -$109.7M -59.13% -880.05% -48.32% -$90.9M
EVAX
Evaxion AS
-- -$1.7M -238.97% -- -54.59% --
GMAB
Genmab AS
$673M $188M 22.23% 22.23% 34.83% $257M
IOBT
IO Biotech
-- -$22.6M -- -- -- -$23.1M
NVO
Novo Nordisk AS
$9.2B $5.5B 53.78% 84.88% 54.06% $1.4B

Galecto vs. Competitors

  • Which has Higher Returns GLTO or ASND?

    Ascendis Pharma AS has a net margin of -- compared to Galecto's net margin of -93.73%. Galecto's return on equity of -- beat Ascendis Pharma AS's return on equity of -880.05%.

    Company Gross Margin Earnings Per Share Invested Capital
    GLTO
    Galecto
    -- -$1.92 --
    ASND
    Ascendis Pharma AS
    82.65% -$1.66 $711.6M
  • What do Analysts Say About GLTO or ASND?

    Galecto has a consensus price target of $8.00, signalling upside risk potential of 167.56%. On the other hand Ascendis Pharma AS has an analysts' consensus of $223.52 which suggests that it could grow by 37.98%. Given that Galecto has higher upside potential than Ascendis Pharma AS, analysts believe Galecto is more attractive than Ascendis Pharma AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    GLTO
    Galecto
    1 1 0
    ASND
    Ascendis Pharma AS
    12 0 0
  • Is GLTO or ASND More Risky?

    Galecto has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ascendis Pharma AS has a beta of 0.407, suggesting its less volatile than the S&P 500 by 59.314%.

  • Which is a Better Dividend Stock GLTO or ASND?

    Galecto has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ascendis Pharma AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galecto pays -- of its earnings as a dividend. Ascendis Pharma AS pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GLTO or ASND?

    Galecto quarterly revenues are --, which are smaller than Ascendis Pharma AS quarterly revenues of $106.2M. Galecto's net income of -$2.5M is higher than Ascendis Pharma AS's net income of -$99.6M. Notably, Galecto's price-to-earnings ratio is -- while Ascendis Pharma AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galecto is -- versus 24.13x for Ascendis Pharma AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GLTO
    Galecto
    -- -- -- -$2.5M
    ASND
    Ascendis Pharma AS
    24.13x -- $106.2M -$99.6M
  • Which has Higher Returns GLTO or EVAX?

    Evaxion AS has a net margin of -- compared to Galecto's net margin of -64.14%. Galecto's return on equity of -- beat Evaxion AS's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    GLTO
    Galecto
    -- -$1.92 --
    EVAX
    Evaxion AS
    -- -$0.40 $74K
  • What do Analysts Say About GLTO or EVAX?

    Galecto has a consensus price target of $8.00, signalling upside risk potential of 167.56%. On the other hand Evaxion AS has an analysts' consensus of $13.25 which suggests that it could grow by 604.79%. Given that Evaxion AS has higher upside potential than Galecto, analysts believe Evaxion AS is more attractive than Galecto.

    Company Buy Ratings Hold Ratings Sell Ratings
    GLTO
    Galecto
    1 1 0
    EVAX
    Evaxion AS
    1 0 0
  • Is GLTO or EVAX More Risky?

    Galecto has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Evaxion AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock GLTO or EVAX?

    Galecto has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evaxion AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galecto pays -- of its earnings as a dividend. Evaxion AS pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GLTO or EVAX?

    Galecto quarterly revenues are --, which are smaller than Evaxion AS quarterly revenues of $3M. Galecto's net income of -$2.5M is lower than Evaxion AS's net income of -$1.9M. Notably, Galecto's price-to-earnings ratio is -- while Evaxion AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galecto is -- versus 0.60x for Evaxion AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GLTO
    Galecto
    -- -- -- -$2.5M
    EVAX
    Evaxion AS
    0.60x -- $3M -$1.9M
  • Which has Higher Returns GLTO or GMAB?

    Genmab AS has a net margin of -- compared to Galecto's net margin of 27.27%. Galecto's return on equity of -- beat Genmab AS's return on equity of 22.23%.

    Company Gross Margin Earnings Per Share Invested Capital
    GLTO
    Galecto
    -- -$1.92 --
    GMAB
    Genmab AS
    94.13% $0.31 $5.3B
  • What do Analysts Say About GLTO or GMAB?

    Galecto has a consensus price target of $8.00, signalling upside risk potential of 167.56%. On the other hand Genmab AS has an analysts' consensus of $29.31 which suggests that it could grow by 40.86%. Given that Galecto has higher upside potential than Genmab AS, analysts believe Galecto is more attractive than Genmab AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    GLTO
    Galecto
    1 1 0
    GMAB
    Genmab AS
    4 4 0
  • Is GLTO or GMAB More Risky?

    Galecto has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Genmab AS has a beta of 1.037, suggesting its more volatile than the S&P 500 by 3.676%.

  • Which is a Better Dividend Stock GLTO or GMAB?

    Galecto has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genmab AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galecto pays -- of its earnings as a dividend. Genmab AS pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GLTO or GMAB?

    Galecto quarterly revenues are --, which are smaller than Genmab AS quarterly revenues of $715M. Galecto's net income of -$2.5M is lower than Genmab AS's net income of $195M. Notably, Galecto's price-to-earnings ratio is -- while Genmab AS's PE ratio is 12.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galecto is -- versus 4.36x for Genmab AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GLTO
    Galecto
    -- -- -- -$2.5M
    GMAB
    Genmab AS
    4.36x 12.37x $715M $195M
  • Which has Higher Returns GLTO or IOBT?

    IO Biotech has a net margin of -- compared to Galecto's net margin of --. Galecto's return on equity of -- beat IO Biotech's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    GLTO
    Galecto
    -- -$1.92 --
    IOBT
    IO Biotech
    -- -$0.34 --
  • What do Analysts Say About GLTO or IOBT?

    Galecto has a consensus price target of $8.00, signalling upside risk potential of 167.56%. On the other hand IO Biotech has an analysts' consensus of $9.50 which suggests that it could grow by 685.12%. Given that IO Biotech has higher upside potential than Galecto, analysts believe IO Biotech is more attractive than Galecto.

    Company Buy Ratings Hold Ratings Sell Ratings
    GLTO
    Galecto
    1 1 0
    IOBT
    IO Biotech
    2 0 0
  • Is GLTO or IOBT More Risky?

    Galecto has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IO Biotech has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock GLTO or IOBT?

    Galecto has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IO Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galecto pays -- of its earnings as a dividend. IO Biotech pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GLTO or IOBT?

    Galecto quarterly revenues are --, which are smaller than IO Biotech quarterly revenues of --. Galecto's net income of -$2.5M is higher than IO Biotech's net income of -$22.4M. Notably, Galecto's price-to-earnings ratio is -- while IO Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galecto is -- versus -- for IO Biotech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GLTO
    Galecto
    -- -- -- -$2.5M
    IOBT
    IO Biotech
    -- -- -- -$22.4M
  • Which has Higher Returns GLTO or NVO?

    Novo Nordisk AS has a net margin of -- compared to Galecto's net margin of 37.18%. Galecto's return on equity of -- beat Novo Nordisk AS's return on equity of 84.88%.

    Company Gross Margin Earnings Per Share Invested Capital
    GLTO
    Galecto
    -- -$1.92 --
    NVO
    Novo Nordisk AS
    83.49% $0.92 $37.3B
  • What do Analysts Say About GLTO or NVO?

    Galecto has a consensus price target of $8.00, signalling upside risk potential of 167.56%. On the other hand Novo Nordisk AS has an analysts' consensus of $89.76 which suggests that it could grow by 33.28%. Given that Galecto has higher upside potential than Novo Nordisk AS, analysts believe Galecto is more attractive than Novo Nordisk AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    GLTO
    Galecto
    1 1 0
    NVO
    Novo Nordisk AS
    4 4 1
  • Is GLTO or NVO More Risky?

    Galecto has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.706%.

  • Which is a Better Dividend Stock GLTO or NVO?

    Galecto has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk AS offers a yield of 2.4% to investors and pays a quarterly dividend of $1.10 per share. Galecto pays -- of its earnings as a dividend. Novo Nordisk AS pays out 43.71% of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios GLTO or NVO?

    Galecto quarterly revenues are --, which are smaller than Novo Nordisk AS quarterly revenues of $11B. Galecto's net income of -$2.5M is lower than Novo Nordisk AS's net income of $4.1B. Notably, Galecto's price-to-earnings ratio is -- while Novo Nordisk AS's PE ratio is 19.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galecto is -- versus 6.89x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GLTO
    Galecto
    -- -- -- -$2.5M
    NVO
    Novo Nordisk AS
    6.89x 19.95x $11B $4.1B

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

UPS Stock Forecast: Is the 6.9% Dividend Too Good to Be True?
UPS Stock Forecast: Is the 6.9% Dividend Too Good to Be True?

Parcel delivery giant UPS (NYSE:UPS) has seen its fair share…

Where Will Coinbase Stock Be in 5 Years?
Where Will Coinbase Stock Be in 5 Years?

If you’ve been anywhere near the crypto world over the…

How High Will Planet Labs Stock Go in 2025?
How High Will Planet Labs Stock Go in 2025?

Today we dive into Planet Labs (NYSE: PL), the satellite…

Stock Ideas

Buy
65
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 38x

Buy
65
Is NVDA Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 45x

Sell
33
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Alerts

Buy
55
SBET alert for May 27

SharpLink Gaming [SBET] is up 429.61% over the past day.

Buy
60
MRUS alert for May 27

Merus NV [MRUS] is down 6.93% over the past day.

Buy
57
RGC alert for May 27

Regencell Bioscience Holdings [RGC] is down 8.85% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock